When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...
22h
Hosted on MSNMonoclonal Antibodies for Early Alzheimer's DiseaseEach episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...
1d
Medpage Today on MSNFor Your Patients: Navigating Treatment Options in Early Stage Alzheimer’s DiseaseWith early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...
Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...
Eisai and Biogen's Alzheimer's therapy Leqembi will be ... The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients ...
Loss of brain volume in people with Alzheimer's disease reflects neurodegeneration. In their Personal View, Christopher R S Belder and colleagues 3 propose a re-interpretation of volume changes in the ...
Swelling caused by brain cancer is a serious problem that can lead to serious side effects and even death. While controlling ...
Low-level light therapy, also called photobiomodulation (PBM), has emerged as a promising approach to Alzheimer's treatment, ...
Two hundred thousand Americans develop Alzheimer’s ... of a causal role for amyloid. Skeptical biologists have proposed alternative mechanisms for the effects of anti-amyloid agents, suggesting ...
The findings could open the door to testing anti-amyloid therapies in FTD patients with plaques ... “It now seems possible to use [plasma p-Tau217] to track the Alzheimer component of any progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results